BUZZ-H.C. Wainwright starts coverage on Virax Biolabs with 'buy' rating

Reuters

Mar 31

BUZZ-H.C. Wainwright starts coverage on Virax Biolabs with 'buy' rating

** H.C. Wainwright starts coverage on biotech firm Virax Biolabs VRAX.O with a "buy" rating and $3 PT, implying a more than twofold upside to stock's last close

** VRAX has an "attractive market opportunity" in post-acute infection syndromes (PAIS) diagnostics, with long COVID potentially contributing to a "hundreds of millions of dollars" market, says brokerage

** PAIS refers to chronic illnesses that occur after an infection, causing prolonged symptoms such as fatigue, pain and cognitive issues

** ViraxImmune, a diagnostic test, is being developed to detect T-cell dysfunction in PAIS, including long COVID, with UK clinical validation study underway, brokerage says

** The test shows promise in evaluating immune status in chronic conditions, with "significant changes" in cytokine levels, which are small proteins that help immune cells communicate, in PAIS patients - H.C. Wainwright

** Over 16 million U.S. and UK patients are affected by long COVID, and 0.5 million may be diagnosed with Lyme disease annually, creating a large market for ViraxImmune - brokerage

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2523129689"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2523129689\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2523129689?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-31 18:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2523129689","market":"us","top_or_hot":-1,"title":"BUZZ-H.C. Wainwright starts coverage on Virax Biolabs with 'buy' rating","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-H.C. Wainwright starts coverage on Virax Biolabs with 'buy' rating</title></head><body><p>** H.C. Wainwright starts coverage on biotech firm Virax Biolabs <span>VRAX.O</span> with a \"buy\" rating and $3 PT, implying a <span>more than twofold </span>upside to stock's last close</p><p>** VRAX has an \"attractive market opportunity\" in post-acute infection syndromes (PAIS) diagnostics, with long COVID potentially contributing to a \"hundreds of millions of dollars\" market, <span>says brokerage</span> </p><p>** PAIS <span>refers </span>to chronic illnesses that occur after an infection, causing prolonged symptoms such as fatigue, pain and cognitive issues</p><p>** ViraxImmune, a diagnostic test, is being developed to detect T-cell dysfunction in PAIS, including long COVID, with UK clinical validation study underway, brokerage says</p><p>** The test shows promise in evaluating immune status in chronic conditions, with \"significant changes\" in cytokine levels, which are small proteins that help immune cells communicate, in PAIS patients - <span>H.C. Wainwright</span></p><p>** Over 16 million U.S. and UK patients are affected by long COVID, and 0.5 million may be diagnosed with Lyme disease annually, creating a large market for ViraxImmune - brokerage</p><p>(Reporting by Kamal Choudhury in Bengaluru)</p><p>((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-H.C. Wainwright starts coverage on Virax Biolabs with 'buy' rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-H.C. Wainwright starts coverage on Virax Biolabs with 'buy' rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-31 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-H.C. Wainwright starts coverage on Virax Biolabs with 'buy' rating</title></head><body><p>** H.C. Wainwright starts coverage on biotech firm Virax Biolabs <span>VRAX.O</span> with a \"buy\" rating and $3 PT, implying a <span>more than twofold </span>upside to stock's last close</p><p>** VRAX has an \"attractive market opportunity\" in post-acute infection syndromes (PAIS) diagnostics, with long COVID potentially contributing to a \"hundreds of millions of dollars\" market, <span>says brokerage</span> </p><p>** PAIS <span>refers </span>to chronic illnesses that occur after an infection, causing prolonged symptoms such as fatigue, pain and cognitive issues</p><p>** ViraxImmune, a diagnostic test, is being developed to detect T-cell dysfunction in PAIS, including long COVID, with UK clinical validation study underway, brokerage says</p><p>** The test shows promise in evaluating immune status in chronic conditions, with \"significant changes\" in cytokine levels, which are small proteins that help immune cells communicate, in PAIS patients - <span>H.C. Wainwright</span></p><p>** Over 16 million U.S. and UK patients are affected by long COVID, and 0.5 million may be diagnosed with Lyme disease annually, creating a large market for ViraxImmune - brokerage</p><p>(Reporting by Kamal Choudhury in Bengaluru)</p><p>((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRAX","symbol_name":"Virax Biolabs Group Limited","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL3N3QE0K9:1","article_id":"2523129689","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2523129689","pubTimestamp":1743418738,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-H.C. Wainwright starts coverage on Virax Biolabs with 'buy' rating** H.C. Wainwright starts coverage on biotech firm Virax Biolabs VRAX.O with a \"buy\" rating and $3 PT, implying a more than twofold upside to stock's last close** VRAX has an \"attractive market opportunity\" in post-acute infection syndromes  diagnostics, with long COVID potentially contributing to a \"hundreds of millions of dollars\" market, says brokerage ** PAIS refers to chronic illnesses that occur after an infection, causing prolonged symptoms such as fatigue, pain and cognitive issues** ViraxImmune, a diagnostic test, is being developed to detect T-cell dysfunction in PAIS, including long COVID, with UK clinical validation study underway, brokerage says** The test shows promise in evaluating immune status in chronic conditions, with \"significant changes\" in cytokine levels, which are small proteins that help immune cells communicate, in PAIS patients - H.C. Wainwright** Over 16 million U.S. and UK patients are ","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"VRAX":"Virax Biolabs Group Limited"},"translate_title":"巴斯-H.C。Wainwright开始对Virax Biolabs给予“买入”评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRAX":0.9},"content_text":"BUZZ-H.C. Wainwright starts coverage on Virax Biolabs with 'buy' rating** H.C. Wainwright starts coverage on biotech firm Virax Biolabs VRAX.O with a \"buy\" rating and $3 PT, implying a more than twofold upside to stock's last close** VRAX has an \"attractive market opportunity\" in post-acute infection syndromes (PAIS) diagnostics, with long COVID potentially contributing to a \"hundreds of millions of dollars\" market, says brokerage ** PAIS refers to chronic illnesses that occur after an infection, causing prolonged symptoms such as fatigue, pain and cognitive issues** ViraxImmune, a diagnostic test, is being developed to detect T-cell dysfunction in PAIS, including long COVID, with UK clinical validation study underway, brokerage says** The test shows promise in evaluating immune status in chronic conditions, with \"significant changes\" in cytokine levels, which are small proteins that help immune cells communicate, in PAIS patients - H.C. Wainwright** Over 16 million U.S. and UK patients are affected by long COVID, and 0.5 million may be diagnosed with Lyme disease annually, creating a large market for ViraxImmune - brokerage(Reporting by Kamal Choudhury in Bengaluru)((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}